Drugs, violence, and a "thumbs up" button will color in the week that lies ahead.

Let's start off the trading week in our lab coats, as we dig into volatile biotech upstart Myogen (NASDAQ:MYOG). In a single day back in December, the stock was bid up 40% higher after the company announced a favorable showing in the phase 3 results on the study of its experimental drug ambrisentan, an experimental treatment for pulmonary arterial hypertension. The condition causes shortness of breath, and if untreated, the grim possibility of heart failure.

Don't tune in for a monster quarter on Monday; analysts expect sharp losses. Do tune in to hear about any more progress on the ambrisentan front.

Investors in Take-Two Interactive (NASDAQ:TTWO) probably feel like one of the innocent motorists who get tossed out of their rides by the car-jacking lead in Grand Theft Auto.

Dude, where's my investment vehicle?

The stock has been rocked as Take-Two and many of the other leading video-game makers are struggling with gamers who have been holding up on buying new titles until all three next-generation consoles hit the market. Tuesday's report will reveal as such. In short, the company may have had a strong holiday quarter showing a year ago, but red ink will spill this time around.

It's mid-week TiVo (NASDAQ:TIVO) time! The digital-video recorder giant will be posting its fiscal fourth-quarter results come Wednesday afternoon. This Motley Fool Stock Advisor pick has been waffling around the single digits for way too long, weighed down by losses from subsidizing hardware sales with heavy rebates to grow its user base. TiVo always seems to have some cool technology to report on, and it seems to partner with all the right companies like Yahoo! (NASDAQ:YHOO) to make its DVR features stand out in a cookie-cutter crowd. Hopefully, we'll learn how far away the company is from closing in on turning cash flow-positive.

We just had a Dueling Fools segment on IMAX (NASDAQ:IMAX), and on Thursday we'll know how 2005 panned out for the big-screen specialist. It should be pretty good. Two weeks ago, the company announced that it was on track to meet -- or beat -- its fourth-quarter targets.

The stock is also an active Motley Fool Rule Breakers selection. As the conventional multiplex cinema fades in popularity, some would argue that the theater business is a bad to place to be, but I believe that a sector worth disrupting is ripe with opportunities.

The end of the trading week brings "the mother of all search engines" to the earnings podium. Mamma.com (NASDAQ:MAMA) will post its fourth-quarter financials on Friday. After a few stateside disappointments from larger search engines last month, it will be interesting to hear how a small fry like Mamma.com is doing.

Until next week, I remain,

Rick Munarriz

Longtime Fool contributor Rick Munarriz recommends windshield wiper fluid when trying to look forward. He does not own shares in any of the companies in this story. The Fool has a disclosure policy. Rick is also part of the Rule Breakers newsletter research team, seeking out tomorrow's ultimate growth stocks a day early.